FDA approves lifileucel, the first tumor-derived T-cell therapy, for advanced melanoma

Evidence stage: Later-Stage HumanRegulatory status: FDA-approved for the exact stated cancer/useGuideline status: Not addressed

The FDA granted accelerated approval to lifileucel (Amtagvi), a one-time, tumor-infiltrating lymphocyte (TIL) cell therapy made from a patient’s own immune cells, for adults with unresectable or metastatic melanoma previously treated with a PD-1-blocking antibody and, if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor. Lifileucel is manufactured by surgically removing a piece of the patient’s own tumor, isolating and expanding the T-cells that have already infiltrated it in a specialized lab process, then infusing billions of those expanded cells back into the patient after a lymphodepleting chemotherapy regimen — the first FDA-approved cellular therapy for a solid tumor of any kind. The approval was supported by the single-arm, open-label, multicohort C-144-01 trial (ClinicalTrials.gov NCT02360579); a pooled analysis of 153 patients across two of the trial’s cohorts (published in the Journal for ImmunoTherapy of Cancer, DOI 10.1136/jitc-2022-005755, PMID 36600653) reported an objective response rate of 31.4%, and the FDA’s own accelerated-approval decision rested specifically on the 73-patient efficacy-evaluable subset of that same trial’s cohort 4.

What This Means

In the single-arm, open-label C-144-01 trial, a one-time infusion of a patient's own expanded tumor-infiltrating lymphocytes (lifileucel) produced an objective response in 31.5% of patients with advanced melanoma who had already progressed on anti-PD-1 immunotherapy — the first time the FDA has approved a cellular therapy of this kind (made directly from a patient's own tumor, not genetically engineered like CAR-T) for a solid tumor.

What This Doesn't Mean

This is a single-arm trial with no randomized comparison group, the basis for an ACCELERATED approval, not a full/traditional approval — continued approval may depend on results from a confirmatory trial verifying clinical benefit. This record makes no claim about lifileucel's effect on overall survival compared with other treatments, which this trial design cannot establish.

Why It Matters

This is the first FDA-approved cellular therapy for ANY solid tumor (prior cell therapies were approved only for blood cancers) and gives patients who have already progressed on standard immunotherapy a genuinely new treatment category to try, in a cancer type — melanoma — that had zero coverage on this site before this record.

Promise & Proof

Proof — strength of the evidence 5 / 5
  • Base score from evidence stage: Later-Stage Human.
  • FDA-approved for the exact stated cancer/use.
Promise — potential significance if later evidence holds up 3 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with unresectable or metastatic melanoma previously treated with a PD-1-blocking antibody and, if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor, given a one-time infusion of lifileucel. The FDA's accelerated approval rested specifically on the 73-patient efficacy-evaluable subset of cohort 4 in the single-arm, open-label, multicohort C-144-01 trial; a separately published pooled analysis combining cohorts 2 and 4 (153 patients total) reported a consistent objective response rate. (Adults)

Requires a specialized, one-time manufacturing process (surgical tumor removal, weeks-long lab expansion of the patient's own T-cells, then lymphodepleting chemotherapy before infusion) available only at specialized treatment centers — not a therapy a patient can simply request from any oncologist. This record does not itself detail the full safety profile (which includes risks from the lymphodepleting chemotherapy and a boxed warning for prolonged, severe cytopenia) and that should be added before publication.

Full evidence details
Study design
Non-randomized trial
Sample size
73

Funding & Conflicts

Sponsor/developer: Iovance Biotherapeutics, Inc. — not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status
FDA-approved for the exact stated cancer/use
Indication
Adults with unresectable or metastatic melanoma previously treated with a PD-1-blocking antibody and, if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
Decision date
2024-02-16
Access notes
Requires specialized, REMS-certified treatment centers due to the manufacturing and lymphodepleting-chemotherapy process involved.
Source
Regulator record (opens in a new tab)

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

FDA approves lifileucel, the first tumor-derived T-cell therapy, for advanced melanoma

https://cancerdiscoveries.com/discoveries/fda-approves-lifileucel-the-first-tumor-derived-t-cell-therapy-for-advanced-melanoma/

Evidence stage: Later-Stage Human

What This Means

In the single-arm, open-label C-144-01 trial, a one-time infusion of a patient's own expanded tumor-infiltrating lymphocytes (lifileucel) produced an objective response in 31.5% of patients with advanced melanoma who had already progressed on anti-PD-1 immunotherapy — the first time the FDA has approved a cellular therapy of this kind (made directly from a patient's own tumor, not genetically engineered like CAR-T) for a solid tumor.

What This Doesn't Mean

This is a single-arm trial with no randomized comparison group, the basis for an ACCELERATED approval, not a full/traditional approval — continued approval may depend on results from a confirmatory trial verifying clinical benefit. This record makes no claim about lifileucel's effect on overall survival compared with other treatments, which this trial design cannot establish.

Why It Matters

This is the first FDA-approved cellular therapy for ANY solid tumor (prior cell therapies were approved only for blood cancers) and gives patients who have already progressed on standard immunotherapy a genuinely new treatment category to try, in a cancer type — melanoma — that had zero coverage on this site before this record.

Primary sources

  • Efficacy and safety of lifileucel, a one-time autologous TIL cell therapy, in patients with advanced melanoma: pooled analysis of consecutive cohorts of the C-144-01 study (Journal for ImmunoTherapy of Cancer) — https://doi.org/10.1136/jitc-2022-005755 (DOI 10.1136/jitc-2022-005755, PMID 36600653)

Date verified: 2026-08-13

Correction status: No correction or retraction